Skip to main content
Terug
Watch Compare

Traws Pharma, Inc.

Datakwaliteit: 100%
TRAW
NASDAQ Manufacturing Chemicals
€ 1,61
▲ € 0,11 (7,33%)
Marktkapitalisatie: 11,93 M
Prijs
€ 1,49
Marktkapitalisatie
11,93 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Revenue declined -0,55% annually over 5 years
Negative free cash flow of -19,47 M
Capital efficient — spends only 0,00% of revenue on capex

Groei

Revenue Growth (5Y)
-0,55%
Onder sectorgemiddelde (1,82%)
Revenue (1Y)0,00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-207,84%
Onder sectorgemiddelde (-54,01%)
ROIC-194,45%
Net Margin-467,64%
Op. Margin-554,64%

Veiligheid

Debt / Equity
N/A
Current Ratio1,22
Interest CoverageN/A

Waardering

PE (TTM|NTM)
-0,90 | -0,34
Boven sectorgemiddelde (-1,49)
P/B Ratio2,62
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1385 peers)
Metriek Aandeel Sector Mediaan
P/E -0,9 -1,5
P/B 2,6 1,6
ROE % -207,8 -54,0
Net Margin % -467,6 -41,5
Rev Growth 5Y % -0,6 1,8
D/E — 0,3

Koersdoel Analisten

2 analisten
Buy
Huidig
€ 1,61
+350.3%
Koersdoel
€ 7,25
€ 6,50
€ 7,25
€ 8,00
Vooruitzicht
Forward K/W -0,34
Forward WPA -€ 4,32
Omzet Sch. 0,0

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2026 -€ 4,32
-€ 4,32 – -€ 4,32
 0,0 1

Winstverassingen

Laatste 1 kwartaal
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q32025 N/A -€ 0,34 —

All Fundamental Metrics
Growth
Revenue Growth (1Y) 0,00% Revenue Growth (3Y) 0,00%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -0,55% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 2,85 M Net Income (TTM) -13,31 M
ROE -207,84% ROA -94,84%
Gross Margin N/A Operating Margin -554,64%
Net Margin -467,64% Free Cash Flow (TTM) -19,47 M
ROIC -194,45% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 1,22
Interest Coverage N/A Asset Turnover 0,20
Working Capital 1,74 M Tangible Book Value 1,97 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,90 Forward P/E -0,34
P/B Ratio 2,62 P/S Ratio 4,19
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -163,22%
Market Cap 11,93 M Enterprise Value 11,93 M
Per Share
EPS (Diluted TTM) 97,19 Revenue / Share 0,36
FCF / Share -2,44 OCF / Share -2,44
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0,00% FCF Conversion 146,27%
SBC-Adj. FCF -20,21 M Growth Momentum 0,55

Income Statement

Annual, most recent first
Metric FY2024 FY2023 FY2021 FY2022 FY2019
Revenue 226.000,0 226.000,0 226.000,0 226.000,0 2,18 M
Net Income -166,52 M -18,95 M -16,16 M -18,96 M -21,50 M
EPS (Diluted) -35,21 -0,90 -0,96 -0,91 —
Gross Profit — — — — —
Operating Income -142,37 M -20,30 M -16,50 M -19,63 M -21,70 M
EBITDA — — — — —
R&D Expenses — 11,43 M 7,30 M 11,41 M 15,54 M
SG&A Expenses — — — — —
D&A 12.000,0 16.000,0 14.000,0 14.000,0 14.000,0
Interest Expense — — — — —
Income Tax — — 4.000,0 — 10.000,0

Balance Sheet

Annual, most recent first
Metric FY2024 FY2023 FY2021 FY2022 FY2019
Total Assets 24,96 M 22,68 M 55,48 M 39,37 M 23,67 M
Total Liabilities 56,59 M 12,01 M 9,36 M 11,06 M 12,10 M
Shareholders' Equity -31,63 M 10,67 M 46,12 M 28,31 M 11,57 M
Total Debt — — — — —
Cash & Equivalents — 20,56 M — 38,52 M —
Current Assets 24,95 M 22,66 M 55,43 M 39,35 M 23,47 M
Current Liabilities 11,53 M 9,22 M 6,12 M 8,05 M 8,29 M